pembrolizumab,pds0101
pds biotech,merck
['head and neck']
 agreed - announced poster presentation of updated data from versatile-002 trial during the 2023 american society of clinical oncology (asco) annual meeting and its selection as a featured poster to be reviewed by an expert panel during the head and neck cancer discussion